Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132801 · ClinicalTrials.gov registry record · NA
Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
A NA study, sponsored by Qualia Life Sciences.
- Not yet
- Registry status
- NA
- Development phase
- 180
- Enrollment target
NCT07132801: Clinical Trial NA study, sponsored by Qualia Life Sciences.
NCT07132801 is a NA study that has not yet begun recruiting, run by Qualia Life Sciences. The registered enrollment target is 180 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07132801, a NA study, has not yet begun recruiting, sponsored by Qualia Life Sciences.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Primary Outcome
To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, or placebo.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Qualia NAD⁺ version 1
- DIETARY_SUPPLEMENT Qualia NAD⁺ version 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2025-12-15 |
| Phase | NA |
What is known before NCT07132801 opens enrollment
NCT07132801 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07132801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07132801 about?
NCT07132801 is a clinical study titled "Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels". This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ vers...
What is the current status of trial NCT07132801?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2025-10-13. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT07132801?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Qualia NAD⁺ version 1 (DIETARY_SUPPLEMENT), Qualia NAD⁺ version 2 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07132801?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07132801's enrollment target sits among peer trials
180 586th of 2000 higher than 1,397 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI